PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score
-
Published:2023-10-09
Issue:19
Volume:12
Page:6420
-
ISSN:2077-0383
-
Container-title:Journal of Clinical Medicine
-
language:en
-
Short-container-title:JCM
Author:
Bayoğlu İbrahim Vedat1, Hüseynov Javid1, Topal Alper2ORCID, Sever Nadiye1, Majidova Nargiz1, Çelebi Abdussamet1, Yaşar Alper1ORCID, Arıkan Rukiye1, Işık Selver1, Hacıoğlu Muhammet Bekir2ORCID, Ercelep Özlem1, Sarı Murat1ORCID, Erdoğan Bülent2, Hacıbekiroğlu İlhan3, Topaloğlu Sernaz2, Köstek Osman1, Çiçin İrfan2ORCID
Affiliation:
1. Department of Medical Oncology, School of Medicine, Marmara University, 34899 Istanbul, Turkey 2. Department of Medical Oncology, School of Medicine, Trakya University, 22000 Edirne, Turkey 3. Department of Medical Oncology, School of Medicine, Sakarya University, 54290 Sakarya, Turkey
Abstract
Introduction: This study aimed to assess the role of the adjusted PNI-IMDC risk scoring system in stratifying the intermediate group of metastatic RCC patients who received TKIS in the first-line setting. Methods: A total of 185 patients were included. The adjusted PNI and IMDC model was used to divide the intermediate group into two groups: intermediate PNI-high and intermediate PNI-low groups. The statistical data were analyzed using Kaplan–Meier and Cox regression analysis. Results: The results showed that the adjusted PNI-IMDC risk score, classic IMDC, and PNI had similar prognostic values. Adjusted PNI-IMDC risk score might be used for a more homogeneous differentiation of the classic intermediate group. On the other hand, multivariate analysis revealed that the presence of nephrectomy, adjusted favorable/intermediate (PNI-high) group, ECOG performance score, and presence of bone metastasis were independent predictors of OS. Conclusions: Pre-treatment PNI, as a valuable and potential add-on biomarker to the adjusted PNI-IMDC classification model, can be helpful for establishing an improved prognostic model for intermediate group mRCC patients treated with first-line TKISs. Further validation studies are needed to clarify these findings.
Reference29 articles.
1. Cancer Statistics, 2017;Siegel;CA Cancer J. Clin.,2017 2. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma;Leibovich;J. Urol.,2010 3. Howlader, N.N.A., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R., and Chen, H.S. (2023, August 30). SEER Cancer Statistics, Review, Based on November 2016 SEER Data Submission, Posted to the SEER Web Site aNCI, Bethesda MAahscgc, Available online: https://seer.cancer.gov/csr/1975_2014/. 4. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma;Motzer;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2002 5. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study;Heng;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2009
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|